ER/PR by IHC & Her2neu by FISH

The ER/PR by IHC & Her2neu by FISH test is a combined diagnostic evaluation used to assess the molecular characteristics of breast and certain other cancers.

• The Estrogen Receptor (ER) and Progesterone Receptor (PR) status are determined using Immunohistochemistry (IHC), a staining method that detects hormone receptor proteins on the surface of tumor cells.
• The HER2/neu gene amplification is detected using Fluorescence In Situ Hybridization (FISH), a genetic test that identifies whether extra copies of the HER2 gene are present in the cancer cells.

Together, these tests help identify whether a tumor is hormone receptor-positive (likely to respond to hormone therapy) or HER2-positive (likely to respond to targeted therapy such as trastuzumab). This combined information allows doctors to plan individualized treatment strategies and predict disease behavior more accurately.

Doctors may recommend the ER/PR by IHC & Her2neu by FISH test for individuals who have been newly diagnosed with breast cancer to determine the hormone receptor status of the tumor. It is also advised for patients with recurrent or metastatic breast cancer to reassess these receptors and guide further treatment. This test helps evaluate how aggressive the cancer is, decide whether hormone therapy or targeted therapy will be effective, and monitor the response to ongoing treatment.

For this test, it is important to provide the clinical history, histopathology report, relevant test reports, and doctor’s prescription at the time of sample collection. A Tata 1mg consolidated Test Requisition Form (TRF) must also be duly filled and submitted along with the sample.

Disclaimer: In no event shall the liability of TATA 1MG exceed the amount of actual cost of test charges incurred by the customer as stated on the invoice issued by Tata 1mg.